Advertisement

Breast Cancer Research and Treatment

, Volume 34, Issue 1, pp 63–69 | Cite as

In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers

  • Wainer Zoli
  • Alberto Flamigni
  • Giovanni Luca Frassineti
  • Paola Bajorko
  • Franca De Paola
  • Carlo Milandri
  • Dino Amadori
  • Anna Gasperi-Campani
Report

Summary

Thein vitro activities of taxol and taxotere in comparison with cisplatin and doxorubicin were assessed in 30 primary tumor cultures from human breast cancers. Both taxanes were much more potent than cisplatin and doxorubicin. Taxotere was 3.1; 296, and 9.6-fold more cytotoxic than taxol, cisplatin, and doxorubicin respectively. The cytotoxic activity observed in our experiments confirms the potential clinical relevance of the two taxanes in the management of breast cancer.

Key words

clonogenic assay primary human breast cancers taxol taxotere 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assemblyin vitro by taxol. Nature 22: 665–667, 1979Google Scholar
  2. 2.
    Wani MC, Taylor HL, Wall ME: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia. Am Chem Soc 93: 2325–2327, 1971Google Scholar
  3. 3.
    National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, NCI, Bethesda, MD 1991Google Scholar
  4. 4.
    Denis JN, Greene AE: A highly efficient approach to natural taxol. J Am Chem Soc 110: 5917–5919, 1988Google Scholar
  5. 5.
    Mangatal L, Adeline MT, Guenard D: Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 45: 4177–4190, 1989Google Scholar
  6. 6.
    Ringel I, Horwitz SP: Studies with RP56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288–291, 1991Google Scholar
  7. 7.
    Bissery MC, Guenard D, Gueritte-Voegelein F: Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845–4852, 1991Google Scholar
  8. 8.
    Stampfer MR, Hallowes RC, Hackett AJ: Growth of normal human mammary cells in culture.In Vitro Cell Dev Biol 16: 415–425, 1980Google Scholar
  9. 9.
    Smith HS, Lan S, Ceriani R, Hackett AJ, Stampfer MR: Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. Cancer Res 41: 4637–4643, 1981Google Scholar
  10. 10.
    Stampfer MR, Hackett AJ, Hancock MC, Leung JP, Edgington TS, Smith HS: Growth of human mammary epithelium in culture and expression of tumor specific properties. Cold Spring Harbor Symposium on Cellular Proliferation 9: 819–929, 1982Google Scholar
  11. 11.
    E.O.R.T.C. Breast Cancer Cooperative Group: Revision of the standards for the assessment of the hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1515, 1980Google Scholar
  12. 12.
    Silvestrini R, Daidone MG, Valentinis B, Ferraris C, DiRe E, Raspagliesi F, Landoni F, Scarfone G, Bolis G: Potential of cell kinetics in the managment of patients with ovarian cancers. Eur J Cancer 28: 386–390, 1992Google Scholar
  13. 13.
    Amadori D, Bonaguri C, Nanni O, Gentilini P, Lundi N, Zoli W, Riccobon A, Vio A, Magni E, Saragoni A: Cell kinetics and hormonal features in relation to pathological stage in breast cancer. Breast Cancer Res Treat 18: 19–25, 1991Google Scholar
  14. 14.
    Smith HS, Lippman ME, Hiller AJ, Stampfer MR, Hackett AJ: Response to doxorubicin of cultured normal and malignant mammary epithelial cells. J Natl Cancer Inst 74: 341–348, 1985Google Scholar
  15. 15.
    Smith HS, Zoli W, Lippman ME, Howlett A, Volpi A, Amadori D: Development and application of a highly efficientin vitro assay for predicting the chemosensitivity of human breast cancers. In: Amadori D, Ravaioli A, Ridolfi R (eds) Strategies in cancer medical therapy: biological bases and clinical implication, 1989Google Scholar
  16. 16.
    Smith HS, Zoli W, Volpi A, Hiller A, Lippman ME, Swain S, Nayall B, Dollbaum C, Hackett AJ, Amadori D: Preliminary correlations of clinical outcome within vitro chemosensitivity of second passage human breast cancer cells. Cancer Res 50: 2943–2948, 1990Google Scholar
  17. 17.
    Zoli W, Volpi A, Bonaguri C, Riccobon A, Savini S, Brizio R, Saragoni A, Medri L, Marra GA, Amadori D: An efficient method for culturing human breast cancer to evaluate antiblastic drug activityin vitro: experience on 136 primary cancers and on 116 recurrences. Breast Cancer Res Treat 17: 231–238, 1990Google Scholar
  18. 18.
    Alberts DS, Chen HS: Tabular summary of pharmacokinetic parameters relevant toin vitro drug testing. In: Salmon S (ed) Cloning of human tumor stem cells. Liss, New York, 1980, pp 351–359Google Scholar
  19. 19.
    Wiernik PII, Schwartz EL, Einzing A, Strauman II, Lipton RB, Dutcher JP: Phase I trial of taxol in patients with advanced malignancies. Cancer Treat Rep 71: 1171–1177, 1987Google Scholar
  20. 20.
    Koechli OR, Sevin BU, Perras JP, Chou TC, Angioli R, Steren A, Untch M, Averette HE: Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell Viability Assay. Breast Cancer Res Treat 28: 21–27, 1993Google Scholar
  21. 21.
    Irvin RJ, Burris H, Eckardt J, Rodriguez G, Weiss G, Koeller J, Von Hoff DD, Kuhn JG: Pharmacokinetics of a 6 hr Taxotere infusion (RP56976, NSC628503). Proc Am Soc Clin Oncol 11: 108a, 1992Google Scholar
  22. 22.
    Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D Jr, Jaiyesimi I, Vreeland F, Bayssas MMG, Raber MN: Phase I trial of taxotere: five-day schedule. JNCI 84: 1781–1788, 1992Google Scholar
  23. 23.
    Silvestrini R, Zaffaroni N, Orlandi L, Saro O:In vitro cytotoxic activity of taxol and taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells 11: 528–535, 1993Google Scholar
  24. 24.
    Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P: Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992–998, 1991Google Scholar
  25. 25.
    Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum CH, Aapro MS, Bissery MC, Rastetter J, Hanauske AR: Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumor cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer (in press)Google Scholar
  26. 26.
    Kelland LR, Abel G: Comparativein vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444–450, 1992Google Scholar
  27. 27.
    Eisenhauer E, Lofters W, Norris B, Muldal A, Letendre F, Vandenburg T, Verma S: Phase II study of taxotere as first line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. (Abstract) Proc ASCO 12: 64, 1993Google Scholar
  28. 28.
    Seidman AD, Hudis C, Crown JPA, Balmaceda C, Lebwohl D, Currie V, Gilewski T, Hakes T, Robles M, Klem K, Lepore J, Norton L: Phase II evaluation of taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer. (Abstract) Proc ASCO 12: 63, 1993Google Scholar
  29. 29.
    Fumoleau P, Chevallier B, Kerbrat T, Dieras V, De Bail N, Bayssas M, Van Glabbeke M: First line chemotherapy with taxotere in advanced breast cancer: A phase II study of the EORTC Clinical Screening Group. (Abstract) Proc ASCO 12: 56, 1993Google Scholar
  30. 30.
    Rowinsky EK, Onetto N, Canetta RM, Arbuck SG: Taxol: The first of taxanes, an important new class of antitumor agents. Semin Oncol 19: 646–662, 1992Google Scholar
  31. 31.
    Holmes FA, Walters RS, Theriault RL: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–18005, 1991Google Scholar
  32. 32.
    Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19: 670–686, 1992Google Scholar
  33. 33.
    Bisset D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ: Phase I pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523–527, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Wainer Zoli
    • 1
  • Alberto Flamigni
    • 2
  • Giovanni Luca Frassineti
    • 1
  • Paola Bajorko
    • 2
  • Franca De Paola
    • 2
  • Carlo Milandri
    • 1
  • Dino Amadori
    • 1
  • Anna Gasperi-Campani
    • 3
    • 4
  1. 1.Department of Medical OncologyG.B. Morgagni-L. Pierantoni HospitalForliItaly
  2. 2.Istituto Oncologico RomagnoloForliItaly
  3. 3.Interdepartmental Center for Research on CancerUniversity of BolognaItaly
  4. 4.Department of Experimental PathologyUniversity of BolognaItaly

Personalised recommendations